Biotechnology
Vitro S.A. sells Cytognos to BD to prioritize the market launch of their new and disruptive Molecular Biology and Anatomic Pathology diagnostic platforms
Cytognos divestment is a first strategic step aimed at positioning Vitro as a
new worldwide diagnostic player in their key market segments
SEVILLE, Spain, Feb. 4, 2022 /PRNewswire/ -- Vitro S.A, (www.vitro.bio
2022-02-04 17:23
5008
Nanoform signs GMP manufacturing program with TargTex following formulation success
HELSINKI, Feb. 4, 2022 /PRNewswire/ -- Nanoform, an innovative nanoparticle medicine enabling company, today announced it has signed a GMP1 manufacturing program (clinical development) to enhance TargTex's Glioblastoma multiforme drug candidate. The program starts with a PoP (Proof of Process) ph...
2022-02-04 15:54
3439
Medicines and Healthcare Products Regulatory Agency Grants Conditional Marketing Authorization for Novavax COVID-19 Vaccine in Great Britain*
* Nuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted)▼ is the first protein-based COVID-19 vaccine authorized inGreat Britain * Novavax and the U.K. Vaccines Taskforce previously announced an agreement for up to 60 million doses * Authorization based on data including an ongoing pivotal Ph...
2022-02-03 21:22
4966
Phenomenex Celebrates 40-Years of Keeping Scientists Happy & What's to Come
TORRANCE, Calif., Feb. 3, 2022 /PRNewswire/ -- Phenomenex, a global life sciences company that offers analytical chemistry solutions for separation and purification, proudly marks its40th anniversary in 2022 with a new mission statement and several exciting strategic initiatives that will deliver...
2022-02-03 06:49
2972
Avidien Technologies Receives $4M Investment from BroadOak Capital Partners
BOSTON, Feb. 2, 2022 /PRNewswire/ -- Avidien announced today a new financing round of$4M from BroadOak Capital Partners. The investment will help Avidien expand its product roadmap, scale commercial production, and better serve research and pharmaceutical clients. Avidien CEO and Founder Rich Co...
2022-02-02 18:49
2732
CordenPharma Completes Acquisition of Three Manufacturing Facilities from Vifor Pharma
LUXEMBOURG, Feb. 2, 2022 /PRNewswire/ -- CordenPharma, a leading, full-service Contract Development & Manufacturing Organization (CDMO) supplying APIs, Excipients, Drug Products, and associated Packaging services, announced today the completion of the acquisition of three manufacturing facilities...
2022-02-02 11:00
4300
World's most trusted source for chemistry information, CAS, launches major biology expansion
CAS SciFinder Discovery Platform™ redefines its role in drug discovery with the inclusion of unique biosequence data collection and capabilities COLUMBUS, Ohio, Feb. 2, 2022 /PRNewswire/ -- CAS, a division of the American Chemical Society specializing in scientific information solutions, announce...
2022-02-02 10:42
3584
AMR Action Fund Appoints Scientific Advisory Board
Members will play a vital role in evaluating potential investments into clinical-stage companies developing urgently needed antibiotics BOSTON, Feb. 1, 2022 /PRNewswire/ -- The AMR Action Fund, the world's largest public-private partnership investing in the development of new antibiotics, today ...
2022-02-01 19:00
3094
Cytiva fuels biotech development in Australia and New Zealand
* VivaZome Therapeutics wins top prize with its potential to provide off-the-shelf regenerative medicines. * Part of Cytiva's BioChallenge global series, the inaugural challenge for the Australia and New Zealand region received 32 applications from various universities and companies. SYDNEY, F...
2022-02-01 07:00
3609
DEBIOPHARM AND ASPEN PARTNER TO LAUNCH PROSTATE CANCER DRUG TRELSTAR® IN SOUTH AFRICA
LAUSANNE, Switzerland and DURBAN, South Africa, Feb. 1, 2022 /PRNewswire/ --
Debiopharm (www.debiopharm.com
2022-02-01 06:00
3703
Denovo Biopharma LLC Announces FDA Approval of IND to Initiate First Biomarker-Guided Global CNS Clinical Trial for Treatment-Resistant Depression (TRD)
SAN DIEGO, Feb. 1, 2022 /PRNewswire/ -- Denovo Biopharma LLC ("Denovo"), a pioneer in applying precision medicine to the development of innovative therapies, today announced that the FDA has authorized the company's investigational new drug (IND) application of DB104 (liafensine) for treatment-r...
2022-02-01 05:30
2847
Pfizer and Alex Therapeutics announce a Strategic Commercial Partnership to provide evidence-based Digital Therapeutics to patients, starting in Germany
STOCKHOLM, Jan. 31, 2022 /PRNewswire/ -- The Stockholm-based Digital Therapeutics (DTx) company Alex Therapeutics and world leading pharmaceutical company Pfizer have joined forces to provide evidence based, clinically validated and personalized digital therapies to patients. Together, the compa...
2022-01-31 18:00
2694
Aurealis Therapeutics and Xbiome Enter into a License and Collaboration Agreement for Aurealis Four-in-One Diabetic Foot Ulcer and Inflammatory Disease Cell and Gene Therapy AUP-16 in Greater China
BASEL, Switzerland, KUOPIO, Finland, and SHENZHEN, China, Jan. 29, 2022 /PRNewswire/ -- Aurealis Therapeutics, a synthetic biology company developing groundbreaking four-in-one cell and gene therapies and Xbiome, an AI-based microbiome drug development company, today announced that the two compan...
2022-01-29 05:28
4768
Ready to Enter the Middle East Market, Vazyme Showcases Its COVID-19 Testing Solutions at Medlab Middle East 2022
DUBAI, UAE, Jan. 28, 2022 /PRNewswire/ -- Leading China-based biotech company Vazyme (688105.SH) participated in the 2022 edition of Medlab Middle East in the Dubai World Trade Centre (DWTC) fromJanuary 24th to 27th, a leading laboratory and flagship exhibition and conference that brings together...
2022-01-28 13:00
5333
HaemaLogiX and Lonza Collaborate to Manufacture KappaMab, a Multiple Myeloma Drug Candidate
* Lonza to manufacture drug substance for clinical supply of HaemaLogiX's lead multiple myeloma drug candidate, KappaMab, at its new state-of-the-art facility inGuangzhou (CN) * HaemaLogiX will leverage Lonza's regulatory expertise, global manufacturing footprint, and extensive experience in ...
2022-01-28 05:30
6855
FDA Grants Breakthrough Therapy Designation for Dizal Pharmaceutical's DZD9008 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon20 Insertion
SHANGHAI, Jan. 27, 2022 /PRNewswire/ -- Dizal Pharmaceutical Co., Ltd. (SHEX:688192) ("Dizal"), today announced that the U.S. Food and Drug Administration ("FDA") has granted Breakthrough Therapy Designation toDZD9008 (Sunvozertinib) for the treatment of patients with locally advanced or metasta...
2022-01-27 21:15
4596
Brii Bio Appoints Karen D. Neuendorff as Chief People Officer and Head of Human Resources
DURHAM, N.C. and BEIJING, Jan. 27, 2022 /PRNewswire/ -- Brii Biosciences
2022-01-27 21:00
5382
Exyte Closes 2021 with Record Order Intake
- Order intake FY 2021 of over €8 billion, more than doubling YOY - Semiconductor and battery boom are main drivers for increased order intake - Outlook continues to be very positive STUTTGART, Germany, Jan. 27, 2022 /PRNewswire/ -- Exyte, a global leader in the design, engineering, and delivery ...
2022-01-27 20:53
4198
Singapore Grants Approval for INDICAID COVID-19 Rapid Antigen Test as Consumer Self-test for SARS-CoV-2 Control
HONG KONG and SINGAPORE, Jan. 26, 2022 /PRNewswire/ -- PHASE Scientific
International LTD
2022-01-26 17:18
3726
Singapore Grants Approval for INDICAID COVID-19 Rapid Antigen Test as Consumer Self-test for SARS-CoV-2 Control
HONG KONG, Jan. 26, 2022 /PRNewswire/ -- PHASE Scientific International LTD
2022-01-26 17:15
3398
Week's Top Stories
Most Reposted
DayOne Secures Over 1GW Renewable Energy in Malaysia in Landmark TNB Partnership
[Picked up by 294 media titles]
2026-06-04 23:55
DayOne Appoints Nicolas Aguzin to Board of Directors, Strengthening Global Governance and Capital Markets Expertise
[Picked up by 281 media titles]
2026-05-29 15:50Pudu Robotics and Shenzhen CTID Co. Ltd Launch the World's First Full-Scenario Robot-Serviced Hotel Project
[Picked up by 275 media titles]
2026-06-01 18:00Creality 3D Successfully Listed in Hong Kong
[Picked up by 271 media titles]
2026-05-29 11:21
Creality Charts Next Decade as AI-Powered Consumer 3D Creative Platform, Hong Kong listing anchors the company's full-stack ecosystem shift
[Picked up by 269 media titles]
2026-05-30 11:58
Most Read
Creality Charts Next Decade as AI-Powered Consumer 3D Creative Platform, Hong Kong listing anchors the company's full-stack ecosystem shift
2026-05-30 11:58
8138
AMTD's Successful Completion of Acquisition of The Ritz-Carlton, Perth, Valued at A$280 Million
2026-05-29 21:50
7552
Creality 3D Successfully Listed in Hong Kong
2026-05-29 11:21
7068
Zhongchao Inc. Announces Pricing of $5 Million Best Efforts Public Offering
2026-05-29 22:00
6681